Reuters Health Information (2005-10-27): CPG 7909 boosts hepatitis B virus vaccine seroprotection in HIV-infected adults
CPG 7909 boosts hepatitis B virus vaccine seroprotection in HIV-infected adults
Last Updated: 2005-10-27 15:04:54 -0400 (Reuters Health)
NEW YORK (Reuters Health) - The CPG 7909 adjuvant
enhances the seroprotection afforded by hepatitis B virus vaccine in
HIV-infected adults receiving antiretroviral therapy, according to a
report in the September 23rd issue of AIDS.
"CPG-containing adjuvants possess great potential to increase the
level and breadth of protection achieved with vaccination," Dr. Curtis
L. Cooper from The Ottawa Hospital, Ontario, Canada, told Reuters
Synthetic oligodeoxynucleotides containing CpG motifs potently
stimulate the innate immune response, the authors explain, and such
oligodeoxynucleotides have shown efficacy as vaccine adjuvants in
preclinical studies in rhesus macaques.
Dr. Cooper and colleagues investigated the safety and efficacy of
CPG 7909 as an adjuvant to Engerix-B hepatitis B virus vaccine in 19
HIV-infected adults. Nineteen HIV-infected adults received vaccine only.
Most subjects reported at least one adverse event during the course
of the study, the results indicate, but most events were of
mild-to-moderate intensity and included local injection site reactions
and influenza-like symptoms.
Antibody to hepatitis B surface antigen was higher at all time
points after the second injection for subjects receiving vaccine with
CPG 7909 than for subjects receiving vaccine alone, the authors report.
All subjects seroconverted by week 10, the report indicates, and
antibody persisted to 48 weeks in all recipients of vaccine plus CPG
7909 and in 17 of 19 recipients of vaccine only.
Similarly, the researchers note, seroprotective titers remained in
all CPG 7909 recipients at 48 weeks versus 12 of 19 (63%) of vaccine
Lymphocyte proliferative responses to ex vivo restimulation with
hepatitis B surface antigen were also more robust in vaccine plus CPG
7909 recipients than in vaccine only recipients.
"CPG-containing oligodeoxynucleotides can be used effectively to
modulate immune responses to vaccination and, potentially, against
infection," Dr. Cooper said. "We have conducted one study with
influenza vaccine and would like to pursue additional studies in high
risk/poor responding populations. We would like to pursue additional
HIV and HCV-related work with CPG adjuvants."
Dr. Cooper added that a phase III study of CPG 7909 is also planned.